DNTH Share Price Performance
US$33.27
6.33 (23.50%)
Price US$33.27
Share PriceUS$33.27
Dianthus Therapeutics, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
DNTH Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Dianthus Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -2.97
- 100.00%
- -2,364.11%
- 0%
About DNTH
- Founded
- 2019
- Employees
- 78
- CEO
- WebsiteView website
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
